The history and future of melanoma staging

Journal of Surgical Oncology

Volumn 86, Issue 4, 2004, Pages 224-235

  Thompson, John F ^a,b   Shaw, Helen M ^a,b   Hersey, Peter ^a,c   Scolyer, Richard A ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Melanoma; Prognosis; Prognostic factors; Staging

Indexed keywords

LACTATE DEHYDROGENASE;

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM;

ANTIGENS, NEOPLASM; FORECASTING; HISTORY, 20TH CENTURY; HUMANS; LACTATE DEHYDROGENASES; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL ONCOLOGY; MELANOMA; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 3042816718     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20082     Document Type: Review

References (88)

1. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
2. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
3. Thompson JF, Stretch JR, Uren RF, et al.: Sentinel node biopsy for melanoma: Where have we been and where are we going? Ann Surg Oncol 2004;11:147S-151S.
4. Allen AC, Spitz S: Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 1953;6:1-45.
5. Ackerman LV, Del Regato JA: Cancer diagnosis, treatment, and prognosis. St Louis: CV Mosby, 1954. pp 184-185.
6. Petersen NC, Bodenham DC, Lloyd OC: Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis. Br J Plast Surg 1962;15:97-116.
7. McNeer G, Das Gupta T: Prognosis in malignant melanoma. Surgery 1964;56:512-518.
8. Mehnert JH, Heard JL: Staging of malignant melanomas by depth of invasion; a proposed index to prognosis. Am J Surg 1965;110:168-176.
9. Bodenham DC: A study of 650 observed malignant melanomas in the South-West region. Ann R Coll Surg Engl 1968;43:218-239.
10. Clark WH, Jr., From L, Bernardino EA, et al.: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-727.
11. McGovern VJ: The classification of melanoma and its relationship with prognosis. Pathology 1970;2:85-98.
12. Breslow A: Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-908.
13. Breslow A, Cascinelli N, van der Esch EP, et al.: Stage I melanoma of the limbs: Assessment of prognosis by levels of invasion and maximum thickness. Tumori 1978;64:273-284.
14. Balch CM, Murad TM, Soong SJ, et al.: A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-742.
15. Smith JL: Histopathology and biologic behaviour of melanoma: Neoplasms of the skin and malignant melanoma. Chicago: Year Book Medical Publishers, 1976.
16. Ketcham AS, Christopherson WO: A staging system for malignant melanoma. World J Surg 1979;3:271-278.
17. International Union Against Cancer. TNM classification of malignant melanoma. 2nd edn. Geneva: International Union Against Cancer, 1978.
18. American Joint Committee on Cancer. Manual for staging of cancer. 2nd edn. Philadelphia: JB Lippincott, 1983.
19. American Joint Committee on Cancer. Manual for staging of cancer. 3rd edn. Philadelphia: JB Lippincott, 1988.
20. Buzaid AC, Ross MI, Balch CM, et al.: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-1051.
21. Balch CM, Buzaid AC, Atkins MB, et al.: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-1491.
22. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
23. Balch CM: Cutaneous melanoma. AJCC cancer staging manual. 6th edn. New York: Springer-Verlag, 2002.
24. Gershenwald JE, Balch CM, Soong SJ, et al.: Prognostic factors and natural history. In: Balch CM, Houghton A, Jr., Sober A, Soong SJ, editors: Cutaneous melanoma. St Louis: Quality Medical Publishing Inc., 2003. pp 25-54.
25. Balch CM, Soong S, Thompson JF: The natural history of melanoma and factors predicting its outcome. In: Thompson JF, Morton DL, Kroon BBR, editors: Textbook of melanoma. London: Martin Dunitz, 2004. pp 181-198.
26. Balch CM, Buzaid AC, Soong SJ, et al.: New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003;21:43-52.
27. McKinnon JG, Yu XQ, McCarthy WH, et al.: Prognosis for patients with thin cutaneous melanoma: Long-term survival data from the New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003;98:1223-1231.
28. Ruiter DJ, Spatz A, van den Oord JJ, et al.: Pathologic staging of melanoma. Semin Surg Oncol 2002;29:370-381.
29. Spatz A, Cook MG, Elder DE, et al.: Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 2003;39:1861-1865.
30. Scolyer RA, Shaw HM, Thompson JF, et al.: Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003;27:1571-1576.
31. Chao C, Martin RC, 2nd, Ross MI, et al.: Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11:259-264.
32. Sondak VK, Taylor JM, Sabel MS, et al.: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-258.
33. Thompson JF, Shaw HM: Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy? Ann Surg Oncol 2004;11:233-235.
34. Slingluff CL, Jr., Vollmer R, Seigler HF: Acral melanoma: A review of 185 patients with identification of prognostic variables. J Surg Oncol 1990;45:91-98.
35. McGovern VJ, Shaw HM, Milton GW, et al.: Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology 1980;4:235-242.
36. Cochran AJ, Wen DR, Herschman HR, et al.: Detection of S100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982;30:295-297.
37. Gershenwald JE, Colome MI, Lee JE, et al.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-2260.
38. Yu LL, Flotte TJ, Tanabe KK, et al.: Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999;86:617-627.
39. Ruiter DJ, Mooi WJ, van Muijen GNP, et al.: Immunohistochemistry and special diagnostic techniques. In: Thompson JF, Morton DL, Kroon BBR, editors: Textbook of melanoma. London: Martin Dunitz, 2004. pp 129-147.
40. Bostick PJ, Morton DL, Turner RR, et al.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-3244.
41. Morton DL, Hoon DS, Cochran AJ, et al.: Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-549.
42. Reintgen DS, Jakub JW, Pendas S, et al.: The staging of malignant melanoma and the Florida melanoma trial. Ann Surg Oncol 2004;11:186S-191S.
43. Azzola MF, Shaw HM, Thompson JF, et al.: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer 2003;97:1488-1498.
44. Francken A-B, Shaw HM, Thompson JF, et al.: The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004;11:426-433.
45. Hofmann U, Szedlak M, Rittgen W, et al.: Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs, and patient survival. Br J Cancer 2002;87:151-157.
46. Buzaid AC, Gershenwald JE, Ross MI: Initial staging investigations. In: Thompson JF, Morton DL, Kroon BBR, editors: Textbook of melanoma. London: Martin Dunitz, 2004. pp 241-246.
47. Olson JA, Coit DG: Metastatic melanoma at distant sites: Follow-up. In: Thompson JF, Morton DL, Kroon BBR, editors: Textbook of melanoma. London: Martin Dunitz, 2004. pp 449-458.
48. Buzaid AC, Tinoco L, Ross MI, et al.: Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13:2104-2108.
49. Lean CL, Bourne R, Thompson JF, et al.: Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. Melanoma Res 2003;13:259-261.
50. Bourne R, Stanwell PT, Stretch JR: In vivo and ex vivo proton magnetic resonance spectroscopy of primary and secondary melanoma. Eur J Radiol, in press.
51. Smith B, Selby P, Southgate J, et al.: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-1229.
52. Brossart P, Keilholz U, Willhauck M, et al.: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993;101:887-889.
53. Brossart P, Schmier JW, Kruger S, et al.: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995;55:4065-4068.
54. Foss AJ, Guille MJ, Occleston NL, et al.: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:155-159.
55. Battayani Z, Grob JJ, Xerri L, et al.: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-447.
56. Sarantou T, Chi DD, Garrison DA, et al.: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997;57:1371-1376.
57. Kunter U, Buer J, Probst M, et al.: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996;88:590-594.
58. Stevens GL, Scheer WD, Levine EA: Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomarkers Prev 1996;5:293-296.
59. Pittman K, Burchill S, Smith B, et al.: Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996;7:297-301.
60. Jung FA, Buzaid AC, Ross MI, et al.: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997;15:2826-2831.
61. Glaser R, Rass K, Seiter S, et al.: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997;15:2818-2825.
62. Reinhold U, Ludtke-Handjery HC, Schnautz S, et al.: The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997;108:166-169.
63. Aubin F, Chtourou M, Teyssier JR, et al.: The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000;10:113-118.
64. Hoon DS, Wang Y, Dale PS, et al.: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-2116.
65. Palmieri G, Strazzullo M, Ascierto PA, et al.: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999;17:304-311.
66. Mellado B, Colomer D, Castel T, et al.: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 1996;14:2091-2097.
67. Curry BJ, Myers K, Hersey P: Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998;16:1760-1769.
68. Curry BJ, Myers K, Hersey P: MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999;17:2562-2571.
69. Hanekom GS, Stubbings HM, Johnson CA, et al.: The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res 1999;9:465-473.
70. Mellado B, Gutierrez L, Castel T, et al.: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999;5:1843-1848.
71. Schittek B, Bodingbauer Y, Ellwanger U, et al.: Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999;141:30-36.
72. Hoon DS, Bostick P, Kuo C, et al.: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60:2253-2257.
73. Brownbridge GG, Gold J, Edward M, et al.: Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled- polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001;144:279-287.
74. Ghossein RA, Bhattacharya S, Coit DG: Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results Cancer Res 2001;158:63-77.
75. Curry BJ, Myers K, Hersey P: Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res 2001;158:211-230.
76. Szenajch J, Jasinski B, Synowiec A, et al.: Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin Chem 2003;49:1450-1457.
77. Szenajch J, Jasinski B, Kozak A, et al.: Multiple RT-PCR tyrosinase testing reveals that melanoma cells circulate in the blood of melanoma patients at the frequency more than 10 times below the detection threshold. Melanoma Res 2002;12:399-401.
78. Palmieri G, Ascierto PA, Perrone F, et al.: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003;21:767-773.
79. Franzke A, Probst-Kepper M, Buer J, et al.: Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998;78:40-45.
80. Deichmann M, Benner A, Bock M, et al.: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891-1896.
81. Litvak DA, Gupta RK, Yee R, et al.: Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 2004;198:27-35.
82. Rote NS, Gupta RK, Morton DL: Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. J Surg Res 1980;29:18-22.
83. Gupta RK: Circulating immune complexes in malignant melanoma. Dis Markers 1988;6:81-95.
84. Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254.
85. Euhus DM, Gupta RK, Morton DL: Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990;45:1065-1070.
86. Faries MB, Gupta RK, Ye X, et al.: Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma. Ann Surg Oncol 2004;11:85-93.
87. Gershenwald JE, Ross MI, Buzaid AC: Staging systems for cutaneous melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors: Textbook of melanoma. London: Martin Dunitz; 2004. pp 164-180.
88. Cochran AJ, Elashoff D, Morton DL, et al.: Individualized prognosis for melanoma patients. Hum Pathol 2000;31:327-331.